HRP20220295T1 - Spojevi 2-formil-3-hidroksifeniloksimetila koji mogu modulirati hemoglobin - Google Patents
Spojevi 2-formil-3-hidroksifeniloksimetila koji mogu modulirati hemoglobin Download PDFInfo
- Publication number
- HRP20220295T1 HRP20220295T1 HRP20220295TT HRP20220295T HRP20220295T1 HR P20220295 T1 HRP20220295 T1 HR P20220295T1 HR P20220295T T HRP20220295T T HR P20220295TT HR P20220295 T HRP20220295 T HR P20220295T HR P20220295 T1 HRP20220295 T1 HR P20220295T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- compound according
- compound
- pharmaceutically acceptable
- continued
- Prior art date
Links
- -1 2-formyl-3-hydroxyphenyloxymethyl compounds Chemical class 0.000 title claims 4
- 102000001554 Hemoglobins Human genes 0.000 title 1
- 108010054147 Hemoglobins Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 50
- 150000003839 salts Chemical class 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Claims (36)
1. Spoj, naznačen time, da je predstavljen formulom I:
[image]
ili izotopno obogaćeni analog, stereoizomer, mješavina stereoizomera, ili farmaceutski prihvatljiva sol svakoga od njih, pri čemu:
X je CH ili N;
Y je CH ili N;
Z je odsutan, CH2, O ili S; i
R1 je mono-hidroksi-(C1-4 alkil), di-hidroksi-(C1-4 alkil), -CH2CH2OCH3, -CH2CH2CN ili
[image]
2. Spoj prema patentnom zahtjevu 1, naznačen time, da X je CH.
3. Spoj prema patentnom zahtjevu 1, naznačen time, da X je N.
4. Spoj prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da Y je CH.
5. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da Y je N.
6. Spoj prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da Z je odsutan, CH2 ili O.
7. Spoj prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da Z je odsutan.
8. Spoj prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time, da Z je CH2.
9. Spoj prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time, da Z je O.
10. Spoj prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time, da Z je S.
11. Spoj prema patentnom zahtjevu 1, naznačen time, da je predstavljen formulom Ia:
[image]
12. Spoj prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da R1 je -CH2OH, -CH2CH2OH, -CH2CH2CN ili
[image]
13. Spoj prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da R1 je -CH2OH ili -CH2CH2OH.
14. Spoj prema bilo kojem od patentnih zahtjeva 1 do 11, naznačen time, da R1 je mono-hidroksi-(C1-4 alkil) ili di-hidroksi-(C1-4 alkil).
15. Spoj prema bilo kojem od patentnih zahtjeva 1 do 11, naznačen time, da R1 je hidroksimetil, 1-hidroksietil, 2-hidroksietil, 1,2-dihidroksietil, 2-hidroksipropil, 3-hidroksipropil, ili 2-hidroksi-2-metilpropil.
16. Spoj prema patentnom zahtjevu 1, ili izotopno obogaćeni analog, stereoizomer, mješavina stereoizomera, ili farmaceutski prihvatljiva sol svakoga od njih, naznačen time, da se bira iz Tablice 1:
Tablica 1
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
17. Spoj prema patentnom zahtjevu 16, naznačen time, da se bira iz Tablice 1.
18. Spoj prema patentnom zahtjevu 1, ili izotopno obogaćeni analog, stereoizomer, mješavina stereoizomera, ili farmaceutski prihvatljiva sol svakoga od njih, naznačen time, da se bira iz Tablice 2:
Tablica 2
[image]
[image]
[image]
[image]
19. Spoj prema patentnom zahtjevu 1, naznačen time, da je predstavljen formulom:
[image]
[image]
[image]
[image]
[image]
ili izotopno obogaćeni analog, stereoizomer, mješavina stereoizomera, ili farmaceutski prihvatljiva sol svakoga od njih.
20. Spoj prema patentnom zahtjevu 1, naznačen time, da je predstavljen formulom:
[image]
[image]
ili farmaceutski prihvatljiva sol svakoga od njih.
21. Spoj prema patentnom zahtjevu 20, naznačen time, da spoj jest:
[image]
ili njegova farmaceutski prihvatljiva sol.
22. Spoj prema patentnom zahtjevu 20, naznačen time, da spoj jest:
[image]
23. Spoj prema patentnom zahtjevu 20, naznačen time, da spoj jest:
[image]
ili njegova farmaceutski prihvatljiva sol.
24. Spoj prema patentnom zahtjevu 20, naznačen time, da spoj jest:
[image]
25. Spoj prema patentnom zahtjevu 20, naznačen time, da spoj jest:
[image]
ili njegova farmaceutski prihvatljiva sol.
26. Spoj prema patentnom zahtjevu 20, naznačen time, da spoj jest:
[image]
27. Spoj prema patentnom zahtjevu 20, naznačen time, da spoj jest:
[image]
ili njegova farmaceutski prihvatljiva sol.
28. Spoj prema patentnom zahtjevu 20, naznačen time, da spoj jest:
[image]
29. Spoj prema patentnom zahtjevu 20, naznačen time, da spoj jest:
[image]
ili njegova farmaceutski prihvatljiva sol.
30. Spoj prema patentnom zahtjevu 20, naznačen time, da spoj jest:
[image]
31. Spoj prema patentnom zahtjevu 20, naznačen time, da spoj jest:
[image]
ili njegova farmaceutski prihvatljiva sol.
32. Spoj prema patentnom zahtjevu 20, naznačen time, da spoj jest:
[image]
33. Farmaceutski pripravak, naznačen time, da sadrži spoj prema bilo kojem od prethodnih patentnih zahtjeva, ili izotopno obogaćeni analog, stereoizomer, mješavinu stereoizomera, ili farmaceutski prihvatljivu sol svakoga od njih, i farmaceutski prihvatljivo pomoćno sredstvo.
34. Farmaceutski pripravak prema patentnom zahtjevu 33, naznačen time, da sadrži spoj prema patentnom zahtjevu 17, i farmaceutski prihvatljivo pomoćno sredstvo.
35. Spoj prema bilo kojem od patentnih zahtjeva 1 do 32, ili izotopno obogaćeni analog, stereoizomer, mješavinu stereoizomera, ili farmaceutski prihvatljivu sol svakoga od njih, ili farmaceutski pripravak prema patentnom zahtjevu 33, naznačen time, da je za uporabu u postupku liječenja bolesti srpastih stanica kod pojedinca kojemu je to potrebno.
36. Spoj ili farmaceutski pripravak prema patentnom zahtjevu 35, naznačen time, da spoj za uporabu jest spoj prema patentnom zahtjevu 17, ili farmaceutski pripravak za uporabu jest farmaceutski pripravak prema patentnom zahtjevu 34.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862769196P | 2018-11-19 | 2018-11-19 | |
| US201962821314P | 2019-03-20 | 2019-03-20 | |
| US201962848773P | 2019-05-16 | 2019-05-16 | |
| US201962883313P | 2019-08-06 | 2019-08-06 | |
| PCT/US2019/062054 WO2020106642A1 (en) | 2018-11-19 | 2019-11-18 | 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin |
| EP19818401.2A EP3880654B1 (en) | 2018-11-19 | 2019-11-18 | 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220295T1 true HRP20220295T1 (hr) | 2022-05-13 |
Family
ID=68848454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220295TT HRP20220295T1 (hr) | 2018-11-19 | 2019-11-18 | Spojevi 2-formil-3-hidroksifeniloksimetila koji mogu modulirati hemoglobin |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10683285B2 (hr) |
| EP (2) | EP4046988A1 (hr) |
| JP (1) | JP2022509091A (hr) |
| KR (1) | KR20210093990A (hr) |
| CN (1) | CN113316568A (hr) |
| AU (1) | AU2019383960A1 (hr) |
| BR (1) | BR112021007044B1 (hr) |
| CA (1) | CA3120380A1 (hr) |
| CO (1) | CO2021007993A2 (hr) |
| CR (1) | CR20210335A (hr) |
| CY (1) | CY1125025T1 (hr) |
| DK (1) | DK3880654T3 (hr) |
| ES (1) | ES2908325T3 (hr) |
| HR (1) | HRP20220295T1 (hr) |
| HU (1) | HUE057323T2 (hr) |
| IL (1) | IL283128A (hr) |
| LT (1) | LT3880654T (hr) |
| MA (1) | MA54231B1 (hr) |
| MD (1) | MD3880654T2 (hr) |
| MX (1) | MX2021005887A (hr) |
| PL (1) | PL3880654T3 (hr) |
| PT (1) | PT3880654T (hr) |
| RS (1) | RS62970B1 (hr) |
| SG (1) | SG11202104705RA (hr) |
| SI (1) | SI3880654T1 (hr) |
| WO (1) | WO2020106642A1 (hr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2015011448A (es) | 2013-03-15 | 2016-06-06 | Global Blood Therapeutics Inc | Compuestos y sus usos para modular la hemoglobina. |
| CN105246477A (zh) | 2013-03-15 | 2016-01-13 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
| CA2903220C (en) | 2013-03-15 | 2023-01-24 | Qing Xu | Aldehyde compounds and uses thereof for the modulation of hemoglobin |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| CN114181195A (zh) | 2014-02-07 | 2022-03-15 | 全球血液疗法股份有限公司 | 一种化合物的结晶多晶型物 |
| MA43373A (fr) | 2015-12-04 | 2018-10-10 | Global Blood Therapeutics Inc | Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde |
| ES2747768T3 (es) | 2017-03-20 | 2020-03-11 | Forma Therapeutics Inc | Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR) |
| US20200129485A1 (en) | 2018-09-19 | 2020-04-30 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
| WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| ES2966707T3 (es) | 2018-10-01 | 2024-04-23 | Global Blood Therapeutics Inc | Moduladores de la hemoglobina para el tratamiento de la drepanocitosis |
| MX2021005887A (es) * | 2018-11-19 | 2021-09-14 | Global Blood Therapeutics Inc | Compuestos de 2-formil-3-hidroxifeniloximetilo capaces de modular hemoglobina. |
| WO2022241278A1 (en) | 2021-05-14 | 2022-11-17 | Global Blood Therapeutics, Inc. | Solid forms of a modulator of hemoglobin |
| WO2022241286A1 (en) | 2021-05-14 | 2022-11-17 | Global Blood Therapeutics, Inc. | Methods of making a modulator of hemoglobin |
| WO2023003332A1 (ko) | 2021-07-19 | 2023-01-26 | 주식회사 바이오앱 | 식물 기반 covid-19 변이 재조합 스파이크 단백질 발현 벡터 및 상기 발현 벡터를 이용한 재조합 단백질 |
| TW202339732A (zh) | 2021-12-10 | 2023-10-16 | 美商全球血液治療公司 | 投予血紅素調節劑的方法 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| EP0022229B1 (en) | 1979-06-29 | 1982-12-08 | The Wellcome Foundation Limited | Substituted phenol ethers, their preparation, intermediates therefor, pharmaceutical compositions containing them and the preparation thereof |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| ZA818741B (en) | 1980-12-18 | 1983-07-27 | Wellcome Found | Pharmaceutical compounds,preparation,use and intermediates therefor and their preparation |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| JPS63258463A (ja) | 1987-04-14 | 1988-10-25 | Kumiai Chem Ind Co Ltd | ２−フエノキシピリミジン誘導体及び除草剤 |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| EP0658559A1 (de) | 1993-12-14 | 1995-06-21 | Chemisch Pharmazeutische Forschungsgesellschaft m.b.H. | Thienothiazinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als 5-dipoxygenase und Cyclooxygenaseinhibitoren |
| YU41801A (sh) | 1998-12-14 | 2003-12-31 | F. Hofman - La Roche Ag. | Derivati fenilglicina |
| RU2001126549A (ru) | 1999-03-31 | 2003-06-20 | БАСФ Акциенгезельшафт (DE) | Замещенные анилиновые соединения |
| MXPA05001544A (es) | 2002-08-08 | 2005-04-19 | Smithkline Beecham Corp | Compuestos de tiofeno. |
| CA2507545C (en) | 2002-12-04 | 2011-06-21 | Virginia Commonwealth University | Use of furfural derivatives as anti-sickling agents |
| EP1636205A1 (en) | 2003-06-12 | 2006-03-22 | Novo Nordisk A/S | Pyridinyl carbamates as hormone-sensitive lipase inhibitors |
| WO2005102305A2 (en) | 2004-04-22 | 2005-11-03 | Allos Therapeutics, Inc. | Compositions of allosteric hemoglobin modifiers and methods of making the same |
| NZ564759A (en) | 2005-06-30 | 2011-08-26 | Prosidion Ltd | GPCR agonists |
| CN100562514C (zh) | 2005-07-22 | 2009-11-25 | 中国科学院上海药物研究所 | 一类取代丙酰胺衍生物、其制备方法和用途 |
| TW200835687A (en) | 2006-11-30 | 2008-09-01 | R Tech Ueno Ltd | Thiazole derivatives and their use as VAP-1 inhibitor |
| US20090069288A1 (en) | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
| WO2009136889A1 (en) | 2008-05-08 | 2009-11-12 | Nova Southeastern University | Specific inhibitors for vascular endothelial growth factor receptors |
| GB0811451D0 (en) | 2008-06-20 | 2008-07-30 | Syngenta Participations Ag | Novel microbiocides |
| TW201033201A (en) | 2009-02-19 | 2010-09-16 | Hoffmann La Roche | Isoxazole-isoxazole and isoxazole-isothiazole derivatives |
| JP6242810B2 (ja) | 2011-12-28 | 2017-12-06 | グローバル・ブラッド・セラピューティクス・インコーポレイテッドＧｌｏｂａｌ Ｂｌｏｏｄ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 置換ベンズアルデヒド化合物および組織酸素化の増加におけるそれらの使用方法 |
| EP2797597B1 (en) | 2011-12-28 | 2020-02-26 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US20150057251A1 (en) | 2013-08-26 | 2015-02-26 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| BR112015021980A2 (pt) * | 2013-03-15 | 2017-07-18 | Global Blood Therapeutics Inc | compostos e seus usos para a modulação de hemoglobina |
| US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| MX2015011448A (es) * | 2013-03-15 | 2016-06-06 | Global Blood Therapeutics Inc | Compuestos y sus usos para modular la hemoglobina. |
| US20140271591A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compositions and methods for the modulation of hemoglobin (s) |
| WO2014145040A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
| US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
| CA2903220C (en) | 2013-03-15 | 2023-01-24 | Qing Xu | Aldehyde compounds and uses thereof for the modulation of hemoglobin |
| US9422279B2 (en) * | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US20160206604A1 (en) | 2013-08-26 | 2016-07-21 | Global Blood Therapeutics, Inc. | Formulations comprising wetting agents and compounds for the modulation of hemoglobin (s) |
| US20160207904A1 (en) | 2013-08-27 | 2016-07-21 | Global Blood Therapeutics, Inc. | Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| US20150141465A1 (en) | 2013-11-18 | 2015-05-21 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9248199B2 (en) | 2014-01-29 | 2016-02-02 | Global Blood Therapeutics, Inc. | 1:1 adducts of sickle hemoglobin |
| CN114181195A (zh) | 2014-02-07 | 2022-03-15 | 全球血液疗法股份有限公司 | 一种化合物的结晶多晶型物 |
| MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
| MA43373A (fr) | 2015-12-04 | 2018-10-10 | Global Blood Therapeutics Inc | Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde |
| TWI825524B (zh) | 2016-05-12 | 2023-12-11 | 美商全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
| TWI778983B (zh) | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| MX2021005887A (es) * | 2018-11-19 | 2021-09-14 | Global Blood Therapeutics Inc | Compuestos de 2-formil-3-hidroxifeniloximetilo capaces de modular hemoglobina. |
-
2019
- 2019-11-18 MX MX2021005887A patent/MX2021005887A/es unknown
- 2019-11-18 DK DK19818401.2T patent/DK3880654T3/da active
- 2019-11-18 CA CA3120380A patent/CA3120380A1/en active Pending
- 2019-11-18 SG SG11202104705RA patent/SG11202104705RA/en unknown
- 2019-11-18 US US16/687,474 patent/US10683285B2/en active Active
- 2019-11-18 MD MDE20210907T patent/MD3880654T2/ro unknown
- 2019-11-18 KR KR1020217018851A patent/KR20210093990A/ko unknown
- 2019-11-18 SI SI201930191T patent/SI3880654T1/sl unknown
- 2019-11-18 PT PT198184012T patent/PT3880654T/pt unknown
- 2019-11-18 EP EP21217304.1A patent/EP4046988A1/en active Pending
- 2019-11-18 RS RS20220126A patent/RS62970B1/sr unknown
- 2019-11-18 PL PL19818401T patent/PL3880654T3/pl unknown
- 2019-11-18 CN CN201980088809.5A patent/CN113316568A/zh active Pending
- 2019-11-18 WO PCT/US2019/062054 patent/WO2020106642A1/en active Application Filing
- 2019-11-18 BR BR112021007044-3A patent/BR112021007044B1/pt active IP Right Grant
- 2019-11-18 HR HRP20220295TT patent/HRP20220295T1/hr unknown
- 2019-11-18 MA MA54231A patent/MA54231B1/fr unknown
- 2019-11-18 EP EP19818401.2A patent/EP3880654B1/en active Active
- 2019-11-18 AU AU2019383960A patent/AU2019383960A1/en active Pending
- 2019-11-18 LT LTEPPCT/US2019/062054T patent/LT3880654T/lt unknown
- 2019-11-18 JP JP2021527206A patent/JP2022509091A/ja active Pending
- 2019-11-18 CR CR20210335A patent/CR20210335A/es unknown
- 2019-11-18 HU HUE19818401A patent/HUE057323T2/hu unknown
- 2019-11-18 ES ES19818401T patent/ES2908325T3/es active Active
-
2020
- 2020-05-04 US US16/865,625 patent/US11548880B2/en active Active
-
2021
- 2021-05-12 IL IL283128A patent/IL283128A/en unknown
- 2021-06-18 CO CONC2021/0007993A patent/CO2021007993A2/es unknown
-
2022
- 2022-02-28 CY CY20221100163T patent/CY1125025T1/el unknown
- 2022-11-21 US US17/991,448 patent/US20230159507A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220295T1 (hr) | Spojevi 2-formil-3-hidroksifeniloksimetila koji mogu modulirati hemoglobin | |
| HRP20150982T1 (hr) | Novi modulatori sfingozin fosfat receptora | |
| MX340965B (es) | Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular. | |
| UY39032A (es) | Compuestos heterocíclicos como agentes antivirales | |
| BR112016003348A2 (pt) | composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos de quantidade efetiva de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica | |
| ECSP045501A (es) | Moduladores de receptores nucleares de hormonas esteroideas triciclicos | |
| NI201000193A (es) | Formulaciones orales de análogos de citidina y métodos de uso de las mismas. | |
| BR112015011179A8 (pt) | composições farmacêuticas aquosas estáveis compreendendo insulina humana ou um análogo ou derivado das mesmas, seu uso e processos para sua preparação | |
| HN2011001358A (es) | Moduladores de aril metil benzoquinazolina alostericos positivos del receptor m1 | |
| TW200607508A (en) | Powder formulations for inhalation, comprising enantiomerically pure beta agonists | |
| RU2014115796A (ru) | Модуляторы ror-гамма | |
| EA200870368A1 (ru) | Антибиотические композиции с модифицированным высвобождением и способ их получения | |
| HRP20110076T1 (hr) | Farmaceutske kombinacije koje sadrže 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol i paracetamol | |
| HRP20212030T1 (hr) | Kombinacija koja sadrži palbociklib i 6-(2,4-diklorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirolidin-3-il]oksifenil]-8,9-dihidro-7h-benzo[7]anulen-2-karboksilnu kiselinu i njezina upotreba u liječenju raka | |
| MX2021013329A (es) | Composiciones de polvo seco de los profarmacos de treprostinil y métodos de uso de las mismas. | |
| BR112022009209A2 (pt) | Derivado de amida e método de preparação e uso do mesmo na medicina | |
| BR112022001568A2 (pt) | Composto, método para preparação do composto, composição farmacêutica, e, uso do composto | |
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| EA202192530A1 (ru) | Соединения, композиции и способы | |
| CO2022008616A2 (es) | Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma | |
| UY38614A (es) | Derivados de benzodiazepinas como inhibidores del rsv | |
| AR071721A1 (es) | Derivados de piridil-prolinamida, composiciones farmaceuticas que los contienen y su uso para el tratamiento de ansiedad, depresion y trastornos del sueno. | |
| HRP20230300T1 (hr) | Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije | |
| MX2021003670A (es) | Derivados biciclicos como moduladores del receptor gabaa a5. | |
| ZA202107431B (en) | Para-aminohippuric acid (pah) as a renal protective substance |